Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009 (Q28476489)

Robert M Grant

9

0 references

Frederick M. Hecht

Frederick M Hecht

11

0 references

Steven G Deeks

10

Steven G Deeks

0 references

Christopher D Pilcher

8

Christopher D Pilcher

0 references

Wendy Hartogensis

4

Wendy Hartogensis

0 references

Peter Bacchetti

5

Peter Bacchetti

0 references

Teri Liegler

2

Teri Liegler

0 references

author name string

Vivek Jain

1

0 references

Lauren Poole

6

0 references

Lisa Loeb

Creative Commons Attribution 4.0 International

7

0 references

language of work or name

English

0 references

publication date

10 December 2010

0 references

published in

PLOS One

0 references

volume

5

0 references

issue

12

0 references

page(s)

e15510

0 references

copyright license

start time

10 December 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Raltegravir: the first HIV type 1 integrase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Raltegravir with optimized background therapy for resistant HIV-1 infection

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Maraviroc for previously treated patients with R5 HIV-1 infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

High rates of forward transmission events after acute/early HIV-1 infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Brief but efficient: acute HIV infection and the sexual transmission of HIV.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Accuracy of the TRUGENE HIV-1 genotyping kit.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Time trends in primary HIV-1 drug resistance among recently infected persons

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Use of laboratory tests and clinical symptoms for identification of primary HIV infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Transmission of drug-resistant HIV-1 is stabilizing in Europe

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3000814

Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey.

2 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0015510

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0015510

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0015510

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0015510

Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0015510

Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0015510

Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0015510

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21170322